BRAINSTORM CELL THERAPEUTICS INC. Income (Loss) from Continuing Operations, Per Basic Share
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.15 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2021-11-15
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, per basic share for the quarter ending 2021-09-30 was -$0.15.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations, per basic share for the quarter ending 2020-09-30 was -$0.14.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month |
|---|---|---|
| 2021-09-30 | -$0.15 10-Q · filed 2021-11-15 | -$0.51 10-Q · filed 2021-11-15 |
| 2020-09-30 | -$0.14 10-Q · filed 2021-11-15 | -$0.70 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |